EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Translating research into therapeutics: the future of ADCs in cancer therapy

Yu-Tzu Tai

Bioconjugation Insights · 2025

DOI: 10.18609/bci.2025.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugation Insights, 2025. Verfasst von Yu-Tzu Tai. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

“ADCs have demonstrated significant success in solid tumors, largely due to our deep understanding of tumor biology and target antigens.” Lauren Coyle, Launch Commissioning Editor, Bioconjugation Insights, speaks with Yu-Tzu Tai, Associate Director, ADC and Translational Research, Oxford Biotherapeutics about the advancements in ADC development for therapeutic use in multiple myeloma and solid tumors. She discusses future directions in overcoming resistance and off-target toxicity through novel targeting and combination strategies. Bioconjugation Insights is a fully Open Access, peer-reviewed journal that has a translational focus, helping to bridge the gaps that exist between discovery research, preclinical R&D, and clinical development stages, and the marketplace beyond.

Zitieren

APA

Tai, Y. (2025). Translating research into therapeutics: the future of ADCs in cancer therapy. Bioconjugation Insights. https://doi.org/10.18609/bci.2025.005

Vancouver

Tai Y. Translating research into therapeutics: the future of ADCs in cancer therapy. Bioconjugation Insights. 2025. doi:10.18609/bci.2025.005

BibTeX
@article{Tai2025,
  author = {Tai, Yu-Tzu},
  title = {Translating research into therapeutics: the future of ADCs in cancer therapy},
  journal = {Bioconjugation Insights},
  year = {2025},
  doi = {10.18609/bci.2025.005}
}
Kostenlos starten →